Thus, CD14+HLA-DRlow/− MDSCs may be used as a novel prognostic marker for the survival of CLL patients and eliminating CD14+HLA-DRlow/− MDSCs may represent a promising strategy for the treatment of CLL patients. The gene discussed is CD14; the disease is B-cell chronic lymphocytic leukemia.